期刊文献+

肿瘤坏死因子样凋亡微弱诱导剂水平和造影剂肾病的相关性

Correlation of tumor necrosis factor-like weak inducer of apoptosis and contrast-induced nephropathy
原文传递
导出
摘要 目的探讨肿瘤坏死因子样凋亡微弱诱导剂(TWEAK)水平和造影剂肾病(CIN)的相关性。方法行冠状动脉(冠脉)造影的慢性肾功能不全患者400例,根据血清TWEAK检测结果分为A组(TWEAK〈450pg/ml,134例)、B组(450pg/ml≤TWEAK〈550pg/ml,133例)和C组(TWEAK≥550pg/ml,133例),比较三组的CIN发生率。结果 400例患者术后发生CIN患者共53例(13.3%),其TWEAK水平高于未发生CIN患者(P〈0.05)。B组住院期间CIN发生率高于A组、低于C组(13.5%vs.8.2%、18.0%)(P〈0.05)。校正年龄、左心室射血分数、糖尿病、肾小球滤过率等因素后,与A组比较,C组冠脉造影后发生CIN的风险显著增加(OR=1.45,95%CI:1.12-2.64,P〈0.01)。结论冠脉造影患者的TWEAK水平和CIN发生率显著相关,高TWEAK水平可能增加冠脉造影后CIN发生率。 Objective To investigate the correlation of tumor necrosis factor-like weak inducer of apoptosis(TWEAK)and contrast-induced nephropathy(CIN).Methods A total of 400 patients with chronic renal failure undergoing coronary angiography(CAG)was divided into three groups of A(TWEAK〈450pg/ml,134cases),B(450pg/ml≤TWEAK〈550pg/ml,133cases)and C(TWEAK≥550pg/ml,133cases).The incidence of CIN was compared among three groups.Results The incidence of CIN was 13.3%in 400 patients.The TWEAK level of the patients with CIN was higher than that in those without CIN(P〈0.05).The incidence of CIN in group B was higher than that in group A and lower than that in group C(13.5% vs.8.2% and 18.0%)(P〈0.05).After adjusted for age,left ventricular ejection fraction,diabetes mellitus,estimated glomerular filtration rate,the risk of postoperative CIN was significantly higher in group C than that in group A(OR=1.45,95%CI:1.12-2.64,P〈0.01).Conclusion Serum level of TWEAK is closely correlated with the incidence of CIN in the patients undergoing CAG.A higher level of serum TWEAK before operation may increase the risk for CIN after CAG.
出处 《江苏医药》 CAS 2016年第8期890-893,共4页 Jiangsu Medical Journal
基金 国家自然科学基金(81370225)
关键词 肿瘤坏死因子样凋亡微弱诱导剂 造影剂肾病 Tumor necrosis factor-like weak inducer of apoptosis Contrast-induced phropathy
  • 相关文献

参考文献10

  • 1杨鲲,刘文娴,任伟.造影剂肾病临床相关因素分析[J].心肺血管病杂志,2012,31(5):560-564. 被引量:17
  • 2Solomon RJ,Mehran R,Natarajan MK,et al.Contrastinduced nephropathy and long-term adverse events:cause and effect[J]?Clin J Am Soc Nephrol,2009,4(7):1162-1169.
  • 3俞娅芬,储腊萍,董文霞,彭俊琼,钱鑫峰,卢国元.尿NGAL和KIM-1对PCI患者术后造影剂肾病的预测价值[J].江苏医药,2015,41(23):2812-2814. 被引量:5
  • 4Hansson GK.Inflammation,atherosclerosis,and coronary artery disease[J].N Engl J Med,2005,352(16):1685-1695.
  • 5Wiley SR,Cassiano L,Lofton T,et al.A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis[J].Immunity,2001,15(5):837-846.
  • 6Chang CF,Lu TM,Yang WC,et al.Gene polymorphisms of interleukin-10and tumor necrosis factor-αare associated with contrast-induced nephropathy[J].Am J Nephrol,2013,37(2):110-117.
  • 7Saritemur M,Un H,Cadirci E,et al.Tnf-αinhibition by infliximab as a new target for the prevention of glycerolcontrast-induced nephropathy[J].Environ Toxicol Pharmacol,2015,39(2):577-588.
  • 8Sanz AB,Izquierdo MC,Sanchez-Nio MD,et al.TWEAKand the progression of renal disease:clinical translation[J].Nephrol Dial Transplant,2014,29(Suppl 1):i54-i62.
  • 9Berzal S,González-Guerrero C,Rayego-Mateos S,et al.TNF-related weak inducer of apoptosis(TWEAK)regulates junctional proteins in tubular epithelial cells via canonical NF-κB pathway and ERK activation[J].J Cell Physiol,2015,230(7):1580-1593.
  • 10Poveda J,Tabara LC,Fernandez-Fernandez B,et al.TWEAK/Fn14and non-canonical NF-kappaB signaling in kidney disease[J].Front Immunol,2013,4:447.

二级参考文献25

  • 1周力,陈晖,张侃,李虹伟.维生素C预防对比剂肾病的临床研究[J].心肺血管病杂志,2010,29(S1):88-88. 被引量:5
  • 2Solomon RJ,Mehran R, Natarajan MK, et al. Contrast induced nephropathy and long-term adverse events:Cause and effect. Clin J Am Soc Nephrol,2009, 4 : 1162-1169.
  • 3Liistro F, Falsini G, Bolognese L. The clinical burden of contrast media induced nephropathy. Ital Heart,2003,4:668-676.
  • 4Briguori C, Aimldi F, Morici N, et al. New Pharmacological proto- cols to prevent or reduce contrast-media nephropathy. Minerva C ardioa.ngiol, 2005,53 : 49 -58.
  • 5Bouzas-Mosquera A, Vaquez-Rodrfguez JM, Calvifio-Santos R, et al. Contrast-induced nephropathy and acute renal failure following emergent cardic catheterization : incidence, risk factors and prog- nosis. Rev Esp Cardiol,2007 ,60 :1026-1034.
  • 6Abe M, Kimura T, Mofimoto T, et al. Incidence of and risk fac- tors for contrast- induced nephropathy after cardiac catheter iza- tion in Japanese patients. Circ J,2009, 73:1518-1522.
  • 7McCullough PA, Adam A, Becker CR, et al. Epidemiology andprognostic implications of contrast-induced nephropathy. Am J Cardiol, 2006,98 : 5K-13K.
  • 8Chong E, Poh KK, Liang S, et al. Risk factorsand clinical out- comes for contrast-induced nephropathy after percmaneous coro- nary intervention in patients with normal serum creatinine. Ann Acad Med Singapore, 2010,39:374-380.
  • 9MueUer C, Buerkle G, Buetmer HJ, et al. Prevention of contrast rnediaassociated nephropathy:randomized companson of hydration regimenlS in 1620 patients undergoing coronary angioplasty. Arch Intern Med ,2002,162:329-336.
  • 10Nyman U, Bjork J, Aspelin P, et al. Contrast medium dose to GFR ratio:a measure of systemic exposure to predict contrast-induced nephropathy after percutaneous coronary intervention. Acta Radi- o1,2008 ,49 :658-667.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部